ARGX Argenx Se
Data as of close
Healthcare · Biological Products, (No Diagnostic Substances)
Argenx Se (ARGX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry. Shares last traded at $874.51, 18.5% below their 52-week high. Over the past year the stock is up 6.6%.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Biological Products, (No Diagnostic Substances) peers
ARGX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Data as of close
| AMGN | Amgen | $251.7B | 28.78 | 6.61 | 23.0% | -0.13% |
| GILD | Gilead Sciences | $211.3B | — | 6.82 | -12.5% | -0.23% |
| MRNA | Moderna | $88.2B | — | — | — | -0.12% |
| RVMD | Revolution Medicines, Inc. | $40.4B | — | — | — | -1.58% |
| BIIB | Biogen | $36.8B | 105.92 | 3.57 | 3.4% | -1.83% |
| EXEL | Exelixis, Inc. | $17.1B | 19.32 | 6.85 | 35.5% | +1.02% |
| NBIX | Neurocrine Biosciences Inc | $14.7B | 20.95 | 3.98 | 19.0% | -0.52% |
| HALO | Halozyme Therapeutics, Inc. | $14.6B | 35.38 | 8.80 | 24.9% | -1.50% |
| TECH | Bio-Techne | $11.4B | 62.76 | 9.39 | 15.0% | -0.03% |
| RGEN | Repligen Corp | $11.1B | — | 13.73 | -1.5% | -2.17% |
| QGEN | Qiagen N.V. | $10.9B | 25.70 | 5.22 | 20.3% | +0.33% |
| KYMR | Kymera Therapeutics, Inc. | $10.9B | — | — | — | +0.68% |
| PCVX | Vaxcyte, Inc. | $9.0B | — | — | — | -2.26% |
| KRYS | Krystal Biotech, Inc. | $8.8B | 38.95 | 18.66 | 47.9% | -10.76% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.